A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs MHAA 4549A (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 9 Jul 2017 to 8 Jan 2018.
    • 02 May 2017 Planned primary completion date changed from 9 Jul 2017 to 8 Jan 2018.
    • 08 Mar 2017 Planned End Date changed from 1 Jul 2017 to 9 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top